These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3117737)

  • 21. Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study.
    Hellman S
    J Clin Oncol; 1985 Dec; 3(12):1569. PubMed ID: 2999345
    [No Abstract]   [Full Text] [Related]  

  • 22. [Effect of radio-immunochemotherapy-using antiferritin antibody combined with anthracycline drugs on hepatocellular carcinoma cell].
    Une Y; Sato Y; Alam S; Nagabuchi E; Hata Y; Uchino J
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):161-3. PubMed ID: 8380685
    [No Abstract]   [Full Text] [Related]  

  • 23. Factors that affect antiferritin localization in four rat hepatoma models.
    Rostock RA; Kopher KA; Bauer TW; Klein JL
    Cancer Drug Deliv; 1985; 2(2):139-45. PubMed ID: 3902194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiferritin immunoglobulin therapy for treatment of hepatoma.
    Held J; McLaughlin P
    Oncol Nurs Forum; 1987; 14(5):27-31. PubMed ID: 2821514
    [No Abstract]   [Full Text] [Related]  

  • 25. A randomized prospective trial comparing full dose chemotherapy to 131I antiferritin: an RTOG study.
    Order S; Pajak T; Leibel S; Asbell S; Leichner P; Ettinger D; Stillwagon G; Herpst J; Haulk T; Kopher K
    Int J Radiat Oncol Biol Phys; 1991 May; 20(5):953-63. PubMed ID: 1850722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01.
    Vriesendorp HM; Herpst JM; Germack MA; Klein JL; Leichner PK; Loudenslager DM; Order SE
    J Clin Oncol; 1991 Jun; 9(6):918-28. PubMed ID: 2033428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iodination of antiferritin by the method of Bolton and Hunter.
    Gonyea-Stewart L
    Clin Chem; 1981 Apr; 27(4):643. PubMed ID: 7471447
    [No Abstract]   [Full Text] [Related]  

  • 28. Dosimetry and treatment planning for 90Y-labeled antiferritin in hepatoma.
    Leichner PK; Yang NC; Frenkel TL; Loudenslager DM; Hawkins WG; Klein JL; Order SE
    Int J Radiat Oncol Biol Phys; 1988 May; 14(5):1033-42. PubMed ID: 2834309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo properties of a human anaplastic thyroid carcinoma cell line transfected with the sodium iodide symporter gene.
    Lee YJ; Chung JK; Shin JH; Kang JH; Jeong JM; Lee DS; Lee MC
    Thyroid; 2004 Nov; 14(11):889-95. PubMed ID: 15671766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Visualization of adrenocortical carcinoma with 131I-adosterol].
    Maruoka S; Nakamura M
    Nihon Igaku Hoshasen Gakkai Zasshi; 1987 Jan; 47(1):57-63. PubMed ID: 3588270
    [No Abstract]   [Full Text] [Related]  

  • 31. Radiolabeled immunoglobulin therapy in patients with Hodgkin's disease.
    Vriesendorp HM; Quadri SM
    Cancer Biother Radiopharm; 2000 Oct; 15(5):431-45. PubMed ID: 11155816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imaging of an adrenal cortical carcinoma and its skeletal metastasis.
    Drane WE; Graham MM; Nelp WB
    J Nucl Med; 1983 Aug; 24(8):710-2. PubMed ID: 6875680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatic visualization after 131I in patients with thyroid carcinoma.
    Maayan ML; Eisenberg J; Lopez EM; Rothschild MA
    N Engl J Med; 1976 Nov; 295(22):1258-9. PubMed ID: 980041
    [No Abstract]   [Full Text] [Related]  

  • 34. Hepatic visualization after 131I in patients with thyroid carcinoma.
    Blum M
    N Engl J Med; 1977 Mar; 296(11):634. PubMed ID: 840249
    [No Abstract]   [Full Text] [Related]  

  • 35. Imaging of metastatic medullary carcinoma of the thyroid with 131I-meta-iodobenzyl guanidine.
    Poston GJ; Thomas AM; Macdonald DW; Karvounaris D; Henderson BL; George P; Lynn JA; Lavender JP
    Nucl Med Commun; 1986 Apr; 7(4):215-21. PubMed ID: 2873544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radioimmunotherapy for hepatocellular carcinoma (HCC) using 131I-anti HCC isoferritin IgG: preliminary results of experimental and clinical studies.
    Liu KD; Tang ZY; Bao YM; Lu JZ; Qian F; Yuan AN; Zhao HY
    Int J Radiat Oncol Biol Phys; 1989 Feb; 16(2):319-23. PubMed ID: 2537805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radioimmunoscintigraphy of xenografted human thyroid carcinoma.
    Koizumi K; Yokoyama K; Watanabe N; Kawabata S; Shuke N; Kinuya S; Aburano T; Tonami N; Hisada K; Sato N
    Ann Nucl Med; 1988 May; 2(1):21-5. PubMed ID: 3275101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease.
    Vriesendorp HM; Morton JD; Quadri SM
    Cancer Res; 1995 Dec; 55(23 Suppl):5888s-5892s. PubMed ID: 7493365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 131I-MIBG and medullary carcinoma of the thyroid.
    Connell JM; Hilditch TE; Elliott A; Semple PF
    Lancet; 1984 Dec; 2(8414):1273-4. PubMed ID: 6150300
    [No Abstract]   [Full Text] [Related]  

  • 40. Dosimetry of 131I-labeled anti-ferritin in hepatoma: a model for radioimmunoglobulin dosimetry.
    Leichner PK; Klein JL; Garrison JB; Jenkins RE; Nickoloff EL; Ettinger DS; Order SE
    Int J Radiat Oncol Biol Phys; 1981 Mar; 7(3):323-33. PubMed ID: 6268576
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.